Careful management of patient expectations is key to achieving optimal outcomes.
Ophthalmology Times: May/June 2025
Ixo-vec shows sustained efficacy and reduces injection burden through 4 years in clinical trials
Intracameral tPA can treat fibrinous clots in severe anterior uveitis.
Changing demographics and increasing trial complexity present challenges and opportunities.
Timely diagnosis and personalized treatment are key to improving visual outcomes.
Deep learning discerns IIH, NAION, and normal eyes using single fundus image.
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Glaukos receives FDA approval for Epioxa topical therapy for keratoconus
2
Dompé's NAION program selected for FDA Commissioner’s National Priority Voucher Program
3
Q&A: Insights from Rajesh K. Rajpal, MD, on an incision-free keratoconus therapy
4
Aurion Biotech releases positive 12-month results from phase 1/2 CLARA trial
5
.png "Optometry Times"){kind=logo}
